Peptide · Approved

Exenatide

One of the first GLP-1 agonists (Byetta/Bydureon), based on exendin-4 from Gila-monster venom.

Key facts

  • Also known as: Byetta, Bydureon
  • Status: Approved
  • Used for: Diabetes (GLP-1)
  • Natural counterpart: A synthetic exendin-4 (Gila-monster venom) that mimics human GLP-1.
  • Target enzyme / receptor: GLP-1 receptor (GLP-1R) — class B GPCR
  • Signalling pathway: Gαs → cAMP → PKA → insulin secretion
    In plain terms: Boosts insulin when sugar is high and curbs appetite.
  • Crystal / cryo-EM structure: Available  PDB 5VAI ↗

Status & safety

This is an approved medicine — prescription-only in most countries. Only use it under a licensed clinician, obtained through a pharmacy.

Research & clinical studies

Explore the biochemistry and clinical evidence for Exenatide — these open live, date-sorted searches, so they always show the latest.

Read research papers on PubMed ↗

Clinical studies (ClinicalTrials.gov) ↗ Google Scholar ↗ Related guide → All peptides & profiles →

Not medical advice. Chemdu is an educational resource and does not sell, prescribe or supply any peptide. Consult a licensed professional about any medicine or supplement.